Insulet Co. (NASDAQ:PODD – Get Free Report) CEO James Hollingshead bought 5,550 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The shares were acquired at an average price of $181.41 per share, for a total transaction of $1,006,825.50. Following the completion of the transaction, the chief executive officer now […]
Insulet (NASDAQ:PODD – Free Report) had its target price cut by Morgan Stanley from $343.00 to $208.00 in a report published on Thursday morning, MarketBeat Ratings reports. They currently have an equal weight rating on the medical instruments supplier’s stock. Other analysts have also issued research reports about the company. StockNews.com started coverage on Insulet […]
Insulet (NASDAQ:PODD – Free Report) had its price target cut by Bank of America from $365.00 to $295.00 in a research report report published on Thursday, MarketBeat.com reports. They currently have a buy rating on the medical instruments supplier’s stock. Other equities research analysts also recently issued reports about the stock. Raymond James reduced their […]
Bessemer Group Inc. boosted its holdings in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 37.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 315 shares of the medical instruments supplier’s stock after purchasing an additional 85 shares during […]
Citigroup upgraded shares of Insulet (NASDAQ:PODD – Free Report) from a neutral rating to a buy rating in a report released on Monday, Marketbeat Ratings reports. They currently have $265.00 price target on the medical instruments supplier’s stock, down from their previous price target of $273.00. A number of other brokerages also recently commented on […]